9-cis-retinoic acid for immune diseases induced cells.

The use of retinoic acid 9-cis and pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof for the manufacture of a medicament for the treatment of exogenous eczema, such as irritant dermatitis, allergic contact dermatitis, tilotico eczema, pompholyx or of endogenous eczema, such as seborrheic eczema, asteatotic eczema and the discoid eczema.